Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis
- PMID: 10201475
- DOI: 10.1111/j.1572-0241.1999.01005.x
Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis
Abstract
Objective: Octreotide has potentially beneficial effects in patients with cirrhosis. However, the effects of octreotide on central hemodynamics and oxygen use have not been established. The present study was undertaken to evaluate the effect of octreotide on central hemodynamics and oxygen use in patients with viral cirrhosis.
Methods: Twenty-five patients with cirrhosis were enrolled in the study. They were randomly assigned to receive either placebo (n = 10) or a continuous infusion of 100 microg/h of octreotide after an initial 100-microg bolus (n = 15). Hemodynamic measurements and oxygenation values were obtained before and 60 min after octreotide or placebo administration.
Results: Placebo administration did not have any effect on hemodynamic and oxygenation values. In patients who received octreotide, systemic hemodynamic values including cardiac index, mean arterial pressure, and systemic vascular resistance were not affected. The mean pulmonary arterial pressure tended to increase after octreotide administration but was statistically insignificant. There was a significant increase in pulmonary arterial vascular resistance, whereas the pulmonary capillary wedge pressure and right atrial pressure were significantly decreased. Arterial oxygen tension, systemic oxygen uptake, and oxygen extraction ratio were significantly decreased after octreotide administration, whereas oxygen transport as well as arterial and mixed venous oxygen contents remained unchanged.
Conclusions: In patients with viral cirrhosis, octreotide administration exerted a significant effect on pulmonary circulation. It also resulted in a decrease in systemic oxygen uptake and oxygen extraction ratio. These results suggested that octreotide may impair tissue oxygenation in patients with viral cirrhosis.
Similar articles
-
Cardiovascular effects of octreotide in patients with hepatic cirrhosis.Hepatology. 1995 May;21(5):1255-60. Hepatology. 1995. PMID: 7737631 Clinical Trial.
-
Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.Pediatrics. 2006 Jul;118(1):e76-84. doi: 10.1542/peds.2005-2795. Epub 2006 Jun 2. Pediatrics. 2006. PMID: 16751617 Clinical Trial.
-
Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.Am J Gastroenterol. 2005 Mar;100(3):631-5. doi: 10.1111/j.1572-0241.2005.41381.x. Am J Gastroenterol. 2005. PMID: 15743362 Clinical Trial.
-
Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.Ann Pharmacother. 2009 Apr;43(4):692-9. doi: 10.1345/aph.1L373. Epub 2009 Mar 18. Ann Pharmacother. 2009. PMID: 19299324 Review.
-
Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects.Semin Nephrol. 1997 Nov;17(6):505-19. Semin Nephrol. 1997. PMID: 9353862 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical